Expertise in
10
conditions

Kang Y. Yu

Wenzhou, CN 
Expertise in
10
conditions
Wenzhou, CN 

Overview

Kang Yu practices practicing medicine in Wenzhou, China.

Ms. Yu is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Hypohidrotic Ectodermal Dysplasia, Acute Promyelocytic Leukemia, Aplasia Cutis Congenita, Bone Marrow Transplant, and Endoscopy.

She is actively involved in clinical research, co-authoring 156 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Wenzhou, China
Other Locations
Shanghai Key Laboratory Of Stomatology, Shanghai, China
No.37, Guoxue Road, Wuhou District, Chengdu, 610041, China
Peking Union Medical College Hospital, Beijing, China
Xi'an, 710048, China
State Key Laboratory Of Fluid Power And Mechatronic Systems, Hangzhou, China
Weizhou, China
P.R. China, Tianjin, 300000, China
Wuxi, 214000, China
State Key Laboratory Of Fluid Power And Mechatronic Systems, China
Shengyang, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Enrollment Status: Unknown
Publish Date: October 08, 2020
Intervention Type: Genetic, Drug
Study Drugs: Fludarabine, Cyclophosphamide
Study Phase: Not Applicable
View 1 Less Clinical Trial

156 Total Publications

ARID1B mutations promote immune evasion in acute myeloid leukemia through upregulating VISTA expression.
ARID1B mutations promote immune evasion in acute myeloid leukemia through upregulating VISTA expression.
Journal: International immunopharmacology
Published: June 11, 2026

Frequently Asked Questions about Kang Y. Yu

Is Kang Y. Yu a top-rated expert for Hypohidrotic Ectodermal Dysplasia?

MediFind is an objective health platform that identifies experts based on real-world data. Kang Y. Yu is classified as an Distinguished expert for Hypohidrotic Ectodermal Dysplasia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kang Y. Yu participate in research or clinical trials?

Yes. Kang Y. Yu has published 156 articles and abstracts on conditions like Hypohidrotic Ectodermal Dysplasia. You can view a list of Kang Y. Yu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Yu's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile